Cargando…
The New and the Old: Platform Cross-Validation of Immunoaffinity MASS Spectrometry versus ELISA for PromarkerD, a Predictive Test for Diabetic Kidney Disease
PromarkerD is a proteomics derived test for predicting diabetic kidney disease that measures the concentrations of three plasma protein biomarkers, APOA4, CD5L and IBP3. Antibodies against these proteins were developed and applied to a multiplexed immunoaffinity capture mass spectrometry assay. In p...
Autores principales: | Bringans, Scott, Peters, Kirsten, Casey, Tammy, Ito, Jason, Lipscombe, Richard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709118/ https://www.ncbi.nlm.nih.gov/pubmed/33126588 http://dx.doi.org/10.3390/proteomes8040031 |
Ejemplares similares
-
A robust multiplex immunoaffinity mass spectrometry assay (PromarkerD) for clinical prediction of diabetic kidney disease
por: Bringans, Scott, et al.
Publicado: (2020) -
Canagliflozin Attenuates PromarkerD Diabetic Kidney Disease Risk Prediction Scores
por: Peters, Kirsten E., et al.
Publicado: (2023) -
PromarkerD Predicts Renal Function Decline in Type 2 Diabetes in the Canagliflozin Cardiovascular Assessment Study (CANVAS)
por: Peters, Kirsten E., et al.
Publicado: (2020) -
Evaluation of the clinical utility of the PromarkerD in-vitro test in predicting diabetic kidney disease and rapid renal decline through a conjoint analysis
por: Fusfeld, Lauren, et al.
Publicado: (2022) -
Comprehensive mass spectrometry based biomarker discovery and validation platform as applied to diabetic kidney disease
por: Bringans, Scott D., et al.
Publicado: (2017)